Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25268703 | 1.00 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL3204138 | 0.73 | SLC7A5 (0.42) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL4956549 | 0.73 | SLC7A5 (0.35) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL11106067 | 0.71 | SLC7A5 (0.41) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL10276464 | 0.71 | SLC7A5 (0.41) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL5508141 | 0.71 | SLC7A5 (0.41) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL27457895 | 0.70 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL7132175 | 0.70 | SLC7A5 (0.39) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 | |
| SCHEMBL7372437 | 0.69 | SLC7A5 (0.42) | SLC1A3SLC1A2SLC1A1SLC7A5 | |
| SCHEMBL31135438 | 0.68 | ALDH1A1 (0.39) | SLC1A3SLC1A2SLC1A1NOS1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | SLC1A3 3716/4885SLC1A2 3522/4885SLC1A1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.